Skip to main content
BMC Cancer logoLink to BMC Cancer
. 2024 Jul 11;24:829. doi: 10.1186/s12885-024-12600-3

Correction: Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy

Yu-An Li 1,#, Chuan Zhao 1,#, Jing-Jing Ge 1, Cheng Li 1, Feng-Jun Xue 1, Shao-Pei Qi 1, Chi Zhao 1, Chen-Chen Kong 1, Jun-Ping Zhang 1,✉
PMCID: PMC11241845  PMID: 38992602

Correction: BMC Cancer 24, 754 (2024)

10.1186/s12885-024-12373-9

Following publication of the original article [1], a typesetting error was reported. The equal contribution statement was missing in the published article. YuAn Li and Chuan Zhao are co-first authors.

The original article [1] has been corrected.

Footnotes

The online version of the original article can be found at 10.1186/s12885-024-12373-9.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yu An Li and Chuan Zhao are co-first authors.

References

  • 1.Li YA, Zhao C, Ge JJ, et al. Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy. BMC Cancer. 2024;24:754. doi: 10.1186/s12885-024-12373-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Cancer are provided here courtesy of BMC

RESOURCES